ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China

ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China

SHANGHAI, March 24, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the successful completion of the Phase III clinical study of AK0901, a novel drug for the treatment of attention deficit hyperactivity...

FuSure Reinsurance Secures Long-Term Insurance Authorization and Upgrades to Composite License from Hong Kong Insurance Authority

FuSure Reinsurance Secures Long-Term Insurance Authorization and Upgrades to Composite License from Hong Kong Insurance Authority

HONG KONG, March 24, 2025 /PRNewswire/ -- FuSure Reinsurance ("FuSure") is pleased to announce that, following four years of steady growth, it has successfully secured a long-term insurance authorization (Class A and Class D) from the Hong Kong...

Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019

Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019

-- U.S. IND clearance and revaccination trial initiation supports the differentiated global opportunity for Clover's RSV PreF vaccine (SCB-1019) utilizing validated Trimer-Tag platform -- -- Evaluation of SCB-1019 as part of a respiratory...

Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14

Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical development. Preclinical highlights: EVM14 induced a...

Volpara Health Announces BOADICEA Integration and Record ECR 2025 Research Presence

Volpara Health Announces BOADICEA Integration and Record ECR 2025 Research Presence

CANBERRA, Australia, March 24, 2025 /PRNewswire/ -- Volpara Health, a global leader in AI-powered breast health solutions and a subsidiary of Lunit, today announced two major milestones: Volpara density is now a validated input to the BOADICEA...

Qn-SOLAR Announces Perovskite Breakthrough to Illuminate "Earth Hour" with Clean Energy

Qn-SOLAR Announces Perovskite Breakthrough to Illuminate "Earth Hour" with Clean Energy

SHANGHAI, March 22, 2025 /PRNewswire/ -- Qn-SOLAR, a rising star in clean energy solutions, has announced a major breakthrough in perovskite solar technology, aligning with the Earth Hour 2025 theme, "Give an Hour for Earth Doing Something You...

Lion Announces Plan to Implement ADS Ratio Change

Lion Announces Plan to Implement ADS Ratio Change

HONG KONG, March 22, 2025 /PRNewswire/ -- Lion Group Holding Ltd. ("Lion" or "the Company") (NASDAQ: LGHL), operator of an all-in-one trading platform that offers a wide spectrum of products and services, today announced that it plans to change the...

Syneron Bio Announces Strategic Collaboration with AstraZeneca

Syneron Bio Announces Strategic Collaboration with AstraZeneca

BEIJING, March 21, 2025 /PRNewswire/ -- Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with the global biopharmaceutical leader AstraZeneca to develop potential first-in-class...

Antengene Announces 2024 Full-Year Financial Results, Proprietary Programs Advancing to Pivotal Trials with Accelerating Multi-market Revenue Ramp Up

Antengene Announces 2024 Full-Year Financial Results, Proprietary Programs Advancing to Pivotal Trials with Accelerating Multi-market Revenue Ramp Up

SHANGHAI and HONG KONG, March 21, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending December 31, 2024, along with several significant milestones achieved in...

51Talk Online Education Group Announces the Results for the Fourth Quarter and Full Year 2024

51Talk Online Education Group Announces the Results for the Fourth Quarter and Full Year 2024

SINGAPORE, March 21, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk" or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, announced its unaudited results for the fourth...

  • 1
  • ...
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • ...
  • 85
  • menu
    menu